In the last trading session, 27.94 million Bristol-Myers Squibb Co. (NYSE:BMY) shares changed hands as the company’s beta touched 0.35. With the company’s per share price at $48.90 changed hands at -$1.94 or -3.82% during last session, the market valuation stood at $99.50B. BMY’s last price was a discount, traded about -66.52% off its 52-week high of $81.43. The share price had its 52-week low at $49.49, which suggests the last value was -1.21% down since then. When we look at Bristol-Myers Squibb Co.’s average trading volume, we note the 10-day average is 13.68 million shares, with the 3-month average coming to 12.05 million.
Analysts gave the Bristol-Myers Squibb Co. (BMY) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.48. If we narrow down to specifics, the data shows that 1 out of 27 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 16 recommended BMY as a Hold, 8 felt it is a Buy and 1 rated the stock as Underweight. Bristol-Myers Squibb Co.’s EPS for the current quarter is expected to be $1.62.
Bristol-Myers Squibb Co. (NYSE:BMY) trade information
Instantly BMY was in red as seen at the end of in last trading. With action -2.49%, the performance over the past five days has been red. The drop to weekly highs of 51.74 on Monday, 11/20/23 subtracted -3.82% to the stock’s daily price. The company’s shares are showing year-to-date downside of -32.04%, with the 5-day performance at -2.49% in the red. However, in the 30-day time frame, Bristol-Myers Squibb Co. (NYSE:BMY) is -13.39% down. Looking at the short shares, we see there were 23.4 million shares sold at short interest cover period of 1.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is $64.05, meaning bulls need an upside of 23.65% from its current market value. According to analyst projections, BMY’s forecast low is $50.00 with $90.00 as the target high. To hit the forecast high, the stock’s price needs a -84.05% plunge from its current level, while the stock would need to soar -2.25% for it to hit the projected low.
Bristol-Myers Squibb Co. (BMY) estimates and forecasts
Data shows that the Bristol-Myers Squibb Co. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -25.70% over the past 6 months, a -2.08% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Bristol-Myers Squibb Co. will fall -11.00%, while the growth in revenue is estimated to hit -9.30% for the next quarter. Year-over-year growth is forecast to reach -11.20% down from the last financial year.
Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of $10.32 billion. 4 analysts are of the opinion that Bristol-Myers Squibb Co.’s revenue for the quarter ending Mar 2024 will be $10.7 billion. The company’s revenue for the corresponding quarters a year ago was $11.41 billion and $11.34 billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -9.50%. The estimates for the next quarter sales put growth at -5.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 37.06%. The 2023 estimates are for Bristol-Myers Squibb Co. earnings to decrease by -2.04%, but the outlook for the next 5-year period is at -0.25% per year.
Bristol-Myers Squibb Co. is expected to release its next quarterly earnings report on February 02. The 4.60% annual yield figure for the share gives it an annual dividend of 2.25. It is important to note, however, that the 4.60% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Bristol-Myers Squibb Co. (NYSE:BMY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.07% of Bristol-Myers Squibb Co. shares while 78.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.26%. There are 78.21% institutions holding the Bristol-Myers Squibb Co. stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 9.75% of the shares, roughly 203.74 million BMY shares worth $13.03 billion.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 8.27% or 172.67 million shares worth $11.04 billion as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. With 65.55 million shares estimated at $4.19 billion under it, the former controlled 3.14% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.39% of the shares, roughly 50.02 million shares worth around $3.2 billion.